## Edgar Filing: ChemoCentryx, Inc. - Form 4

ChemoCent Form 4	tryx, Inc.										
January 06,											
FORM	<b>A</b> 4 UNITED	STATES	S SECUI	RITIES A	AND EX	СНА	NGE CO	OMMISSION		PPROVAL	
Check t					n, D.C. 20				Number:	3235-0287	
if no lor subject Section Form 4 Form 5 obligation	Section 1	SECU 16(a) of t	<b>RITIES</b> he Securi	<b>ERSHIP OF</b> Act of 1934,	Expires: January 3 20 Estimated average burden hours per response 0						
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 1(b).											
(Print or Type Responses)											
KANAYA SUSAN M Symb					d Ticker or		0	5. Relationship of Reporting Person(s) to Issuer			
				•	Inc. [CC.	XIJ		(Check all applicable)			
				of Earliest T Day/Year)	Fransaction			Director 10% Owner			
C/O CHEMOCENTRYX, INC., 850 ( MAUDE AVENUE				2016			i	_X_Officer (give titleOther (specify below) below)			
WINCEL 1			4 TE A	J 4 T		.1			ince, CFO and		
				-				6. Individual or Joint/Group Filing(Check Applicable Line)			
MOUNTAIN VIEW, CA 94043 MOUNTAIN VIEW, CA											
(City)	(State)	(Zip)	Tab	le I - Non-	Derivative	Secur	ities Acqu	ired, Disposed of,	or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Transaction Date 2A. Deemed			Code (Instr. 3, 4 and 5)				6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
~				Code V	Amount	(D)	Price	(Instr. 3 and 4)			
Common Stock	01/04/2016			М	10,490	А	\$ 2	10,490	D		
Common Stock	01/04/2016			S <u>(1)</u>	10,490 (2)	D	\$ 7.3765 (3)	0	D		
Common Stock	01/05/2016			М	34,341	А	\$ 2	34,341	D		
Common Stock	01/05/2016			S <u>(1)</u>	34,341 (2)	D	\$ 6.8977 (4)	0	D		
	01/06/2016			М	2,776	А	\$ 2	2,776	D		

Edgar Filing: ChemoCentryx, Inc Form
--------------------------------------

Common Stock											
Common Stock	01/06/20	016	S <u>(1)</u>	2,776 (2)	D	\$ 6.5544 (5)	0		D		
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)											
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned   (e.g., puts, calls, warrants, options, convertible securities)											
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactie Code (Instr. 8)	orDeri Secu Acqu or D (D)	rities uired (A) isposed of r. 3, 4,	Expir	te Exercisab ation Date th/Day/Year		7. Title and A Underlying S (Instr. 3 and	Securities
				Code V	(A)	(D)	Date ]	Exercisable	Expiration Date	Title	Amount or Number of Share
Stock Option (right to buy)	\$ 2	01/04/2016		М		10,490	02/0	9/2006 <u>(6)</u>	02/09/2016	Common Stock	10,490
Stock Option (right to buy)	\$ 2	01/05/2016		М		34,341	02/0	9/2006 <u>(6)</u>	02/09/2016	Common Stock	34,34
Stock Option (right to buy)	\$ 2	01/06/2016		М		2,776	02/0	9/2006 <u>(6)</u>	02/09/2016	Common Stock	2,776

## **Reporting Owners**

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
KANAYA SUSAN M C/O CHEMOCENTRYX, INC. 850 MAUDE AVENUE MOUNTAIN VIEW, CA 94043			SVP, Finance, CFO and Sec.					

## Signatures

/s/ Susan M. Kanaya

\*\*Si

Repor

01/06/2016

gnature of	
ting Person	

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported in this Form 4 were effected pursuant to a December 2014 Rule 10b5-1 trading plan adopted by the Reporting Person.
- (2) Shares sold are associated with stock options which will expire in February 2016.

Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from \$7.15 to \$8.00(3) per share, inclusive. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from \$6.69 to \$7.16(4) per share, inclusive. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from \$6.36 to \$6.82(5) per share, inclusive. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

- (6) As of January 4, 2016 and prior to this transaction, the option fully vested
- (7) Not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.